Skip to main content

Table 3 Number of patients with PD-L1/PD-1 positive tumors and stroma

From: Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer

 

Pre-NAC cohort (n = 6)

Post-NAC cohort (n = 17)

Overall PD-L1+

4 (66.7%)

9 (52.9%)

Intratumoral PD-L1+

3 (50.0%)

5 (29.4%)

Stromal PD-L1+

4 (66.7%)

10 (58.8%)

Overall PD-1+

2 (33.3%)

4 (23.5%)

  1. Values are denoted as the number of patients in each group with percentage of cohort that is PD-L1 or PD-1 positive in the parentheses
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us